TABLE 1.
Estimated overall seroprevalence and corresponding percentages of COVID‐19 vaccinations and confirmed COVID‐19 cases by age, Norway
| Age (years) | Positive samples | Number of samples tested (%) | Positive samples, % (95% CI) | Estimated seroprevalence, % (95% credible interval) | Percentage of the Norwegian population vaccinated with the first dose of COVID‐19 vaccine a | Percentage of confirmed COVID‐19 cases in the Norwegian population b |
|---|---|---|---|---|---|---|
| All | 1029 | 1926 (100.0) | 53.4 (51.2–55.7) | 62.6 (60.1–65.2) c | 58.4 | 2.3 |
| 0–11 | 47 | 385 (20.0) | 12.2 (9.1–15.9) | 12.5 (9.3–16.1) | 0 d | 1.8 |
| 12–17 | 25 | 190 (9.9) | 13.2 (8.7–18.8) | 13.6 (9.0–18.9) | 0.5 | 3 |
| 18–44 | 441 | 715 (37.1) | 61.7 (58.0–65.3) | 63.4 (59.6–67.1) | 51.3 | 3.3 |
| 45–64 | 258 | 327 (17.0) | 78.9 (74.1–83.2) | 81.0 (76.0–85.6) | 85.6 | 2.1 |
| ≥65 | 258 | 309 (16.0) | 83.5 (78.9–87.5) | 85.7 (81.2–90.0) | 93.8 | 0.8 |
a
Data from SYSVAK, vaccinations by 15 July 2021.
b
Data from Beredt C19, confirmed COVID‐19 cases by 15 July 2021.
c
The overall seroprevalence for Norway was adjusted for age, sex and county.
d
COVID‐19 vaccines were not approved for use in children under 12 years.